Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Caseinolytic peptidase X (ClpX) is a highly conserved AAA+ (ATPases Associated with diverse cellular Activities) ATPase that serves as a critical molecular chaperone and regulatory subunit within the ClpXP protease complex (UniProt, 2023). Its primary biological function involves the recognition, unfolding, and translocation of specific protein substrates into the proteolytic chamber of ClpP for degradation (Bhandari et al., 2018). This process is essential for maintaining bacterial proteostasis, managing stress responses, and regulating the cell cycle by degrading key proteins like FtsZ (Sass et al., 2011). In many pathogenic bacteria, such as Staphylococcus aureus and Mycobacterium tuberculosis, ClpX is indispensable for survival and virulence, making it an attractive target for the development of next-generation antibiotics (Gao et al., 2015). Pharmacological modulation of ClpX typically involves either the inhibition of its ATPase-driven unfolding activity or the disruption of its interaction with ClpP, which can lead to the accumulation of toxic protein aggregates or uncontrolled proteolysis (Brötz-Oesterhelt & Sass, 2014). While ClpX presents a high-value target for treating multi-drug resistant infections, drug design must ensure selectivity to avoid interfering with the human mitochondrial homolog, hClpX, which could lead to host toxicity (Kurat et al., 2017).
Inhibition of ATPase activity and protein unfolding, or disruption of the ClpXP protease complex assembly to prevent regulated protein degradation; alternatively, some drugs (ADEPs) bind the associated ClpP core to displace ClpX and cause dysregulated proteolysis.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caseinolytic peptidase X (ClpX).